Clinical Trial Update: Trametinib in Increasing Tumoral Iodine Incorporation in Patients With Recurrent or Metastatic Thyroid Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating trametinib for increasing tumoral iodine incorporation in patients with recurrent or metastatic thyroid cancer; results have been poste…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Follicular Thyroid Carcinoma
• Papillary Thyroid Carcinoma
• Poorly Differentiated Thyroid Carcinoma

Drugs mentioned

• MEKINIST (trametinib)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Metastatic Thyroid Gland Carcinoma, Poorly Differentiated Thyroid Gland Carcinoma | Phase 2 | Status: ACTIVE_NOT_RECRUITING | Results posted: 2022-12-28